Cloacogenic carcinoma

Summary

Cloacogenic carcinoma (MONDO:0004129) is a cancer and 4 clinical trials. Top therapeutic interventions include nivolumab and fludeoxyglucose f 18. A subtype of anal canal carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cloacogenic carcinoma
Mondo ID	MONDO:0004129
MeSH	C563020
DOID	DOID:7173
ICD-11	1771267581
NCIT	C8255
UMLS	C0334273
MedGen	90755
GARD	0023838
Is cancer (heuristic)	yes

Also known as: anal canal cloacogenic cancer · anal canal cloacogenic carcinoma · anal cloacogenic carcinoma · cloacogenic anal carcinoma · cloacogenic carcinoma · cloacogenic carcinoma (morphologic abnormality) · cloacogenic carcinoma of anus · cloacogenic carcinoma of the anus

Disease family

This is a subtype of anal canal carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › intestinal cancer › anal canal cancer › anal canal carcinoma › cloacogenic carcinoma

Related subtypes (4): anal canal adenocarcinoma, anal canal neuroendocrine neoplasm, anal canal squamous cell carcinoma, anal canal carcinoma in situ

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03233711	PHASE3	ACTIVE_NOT_RECRUITING	Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT04444921	PHASE3	ACTIVE_NOT_RECRUITING	EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
NCT04166318	PHASE2	ACTIVE_NOT_RECRUITING	Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT02560298	PHASE2	UNKNOWN	Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NIVOLUMAB	4	2
FLUDEOXYGLUCOSE F 18	4	1